Association between plasma levels and immunolocalization of cytokines in heart valve lesions: A possible target for treatment?

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 10, 2008, Pages 1209-1215

  Toli, Konstantina ^a   Paraskevas, Kosmas I ^b   Poulakou, Maria V ^b   Agrogiannis, Georgios ^b   Kavantzas, Nikolaos ^b   Xanthopoulos, Vassilios ^a   Iliopoulos, Dimitrios G ^b   Mantas, Ioannis ^b   Papachristodoulou, Antonios ^b   Patsouris, Efstratios ^b   Mikhailidis, Dimitri P ^c   Perrea, Despina N ^b  

^a General Hospital of Chalkida   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cytokines; Heart valve lesions; Interleukin 10; Interleukin 6; Statins; Tumor necrosis factor

Indexed keywords

CALCIUM; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; AORTA VALVE STENOSIS; ARTICLE; CALCIFICATION; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; HEART VALVE REPLACEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE STENOSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SEX DIFFERENCE; TISSUE LEVEL; VALVULAR HEART DISEASE;

ADULT; AGED; AGED, 80 AND OVER; CYTOKINES; FEMALE; HEART VALVE DISEASES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-10; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 54449096893     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.10.1209     Document Type: Article

References (46)

1. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons, Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006;114:e84-231
2. Branch KR, O'Brien KD, Otto CM. Aortic valve sclerosis as a marker of active atherosclerosis. Curr Cardiol Rep 2002;4:111-7
3. Novaro GM, Griffin BE Calcific aortic stenosis: another face of atherosclerosis? Cleve Clin J Med 2003;70:471-7
4. Prasad Y, Bhalodkar NC. Aortic sclerosis - a marker of coronary atherosclerosis. Clin Cardiol 2004;27:671-3
5. Davutoglu V, Celik A, Aksoy M. Contribution of selected inflammatory mediators to the progression of chronic rheumatic valve disease, subsequent valve calcification and NYHA functional class. J Heart Valve Dis 2005;14:251-6
6. Fae KC, Oshiro SE, Toubert A, et al. How an autoimmune reaction triggered by molecular mimicry between streptococcal M protein and cardiac tissue proteins leads to heart lesions in rheumatic heart disease. J Autoimmun 2005;24:101-9
7. Chen D, Assad-Kotmer C, Orrego C, Torre-Amione G. Cytokines and acute heart failure. Crit Care Med 2008;36:S9-16
8. Rawczynska-Englert I, Hryniewiecki T, Dzierzanowska D. Evaluation of serum cytokine concentrations in patients with infective endocarditis. J Heart Valve Dis 2000;9:705-9
9. Chen MC, Chang HW, Wu CJ, et al. Balance between plasma levels of tumor necrosis factor-α and interleukin-10 in rheumatic mitral stenosis. Cardiology 2005;104:171-5
10. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications Part I: Report of a WHO Consultation: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Heath Org., 2006. Available from: http://www.who.int/diabetes/ publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf [Last accessed 31 July 2008]
11. Wallby L, Janerot-Sjoberg B, Steffensen T, Broqvist M. T Lymphocyte infiltration in non-rheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves. Heart 2002;88:348-51
12. Warren BA, Yong JL. Calcification of the aortic valve: its progression and grading. Pathology 1997;29:360-8
13. Popa C, Netea MG, van Riel PL, et al. The role of TNF-α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 2007;48:751-62
14. Ghezzi P, Cerami A. Tumor necrosis factor as a pharmacological target. Mol Biotechnol 2005;31:239-44
15. Mei CL, Chen ZJ, Liao YH, et al. Interleukin-10 inhibits the down-regulation of ATP binding cassette transporter A1 by tumour necrosis factor-alpha in THP-1 macrophage-derived foam cells. Cell Biol Int 2007;31:1456-61
16. Shkoda A, Ruiz PA, Daniel H, et al. Interleukin- 10 blocked endoplasmic reticulum stress in intestinal epithelial cells: impact on chronic inflammation. Gastroenterology 2007;132:190-207
17. Yndestad A, Damas JK, Oie E, et al. Role of inflammation in the progression of heart failure. Curr Cardiol Rep 2007;9:236-41
18. Balakumar P, Singh M. Anti-tumour necrosis factor-α therapy in heart failure: future directions. Basic Clin Pharmacol Toxicol 2006; 99:391-7
19. Von Haehling S, Jankowska EA, Anker SD. Tumour necrosis factor-α and the failing heart - pathophysiology and therapeutic implications. Basic Res Cardiol 2004;99:18-28
20. Petersen JW, Felker GM. Inflammatory markers in heart failure. Congest Heart Fail 2006;12:324-8
21. Batista ML Jr, Santos RV, Cunha LM, et al. Changes in the pro-inflammatory cytokine production and peritoneal macrophage function in rats with chronic heart failure. Cytokine 2006;23:284-90
22. Kaden JJ, Kilic R, Sarikoc A, et al. Tumor necrosis factor alpha promotes an osteoblast-like phenotype in human aortic valve myofibroblasts: a potential regulatory mechanisms of valvular calcification. Int J Mol Med 2005;16:869-72
23. Kaden JJ, Dempfle CE, Grobholz R, et al. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol 2005;14:80-7
24. Bellamy MF, Pellikka PA, Klarich KW, et al. Association of cholesterol levels hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002;40:1723-30
25. Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007;49:554-61
26. Yilmaz MB, Guray U, Guray Y, et al. Lipid profile of patients with aortic stenosis might be predictive of rate of progression. Am Heart J 2004;147:915-8
27. Helske S, Kupari M, Lindstedt KA, Kovanen PT. Aortic valve stenosis: an active atheroinflammatory process. Curr Opin Lipidol 2007;18:483-91
28. Rosenhek R, Baumgarmer H. Aortic sclerosis, aortic stenosis and lipid-lowering therapy. Expert Rev Cardiovasc Ther 2008;6:385-90
29. Paraskevas KI, Tzovaras AA, Briana DD, Mikhailidis DP. Emerging indications of statins: a pluripotent family of agents with several potential applications. Curr Pharm Des 2007;13:3622-36
30. Alnaeb ME, Alobaid N, Seifalian AM, et al. Statins and peripheral arterial disease: potential mechanisms and clinical benefits. Ann Vasc Surg 2006;20:696-705
31. Gazi IF, Liberopoulos EN, Athyros VG, et al. Statins and solid organ transplantation. Curr Pharm Des 2006;12:4771-83
32. Paraskevas KI. Applications of statins in cardiothoracic surgery: more than just lipid-lowering. Eur J Cardiothorac Surg 2008;33:377-90
33. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opin Ther Targets 2007;11:1143-60
34. Novaro GM, Tiong IY, Pearce GL, et al. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001;104:2205-9
35. Rajamannan NM, Subramaniam M, Caira F, et al. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 2005;112(9 Suppl):I229-34
36. Rajamannan NM, Subramaniam M, Stock SR, et al. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 2005;91:806-10
37. Li JJ, Li YS, Fang CH, et al. Effects of simvastatin within two weeks on anti-inflammatory cytokine interleukin 10 in patients with unstable angina. Heart 2006;92:529-30
38. Li JJ, Fang CH. Effects of 4 weeks of atorvastatin administration on the antiinflammatory cytokine interleukin- 10 in patients with unstable angina. Clin Chem 2005;51:1735-8
39. Ascer E, Bertolami MC, Venturinelli ML, et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 2004;177:161-6
40. Chua D, Kalb K. Statins and progression of calcified aortic stenosis. Ann Pharmacother 2006;40:2195-9
41. Mohler ER 3rd, Wang H, Medenilla E, Scott C. Effect of statin treatment on aortic valve and coronary artery calcification. J Heart Valve Dis 2007;16:378-86
42. Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007;49:554-61
43. Antonini-Canterin F, Corrado G, Faggiano P, et al. A medical therapy for aortic valve sclerosis and aortic valve stenosis? Rationale of the ASSIST study (Asymptomatic aortic Sclerosis/Stenosis: Influence of STatins): a large, observational, prospective, multicenter study of the Italian Society of Cardiovascular Echography. J Cardiovasc Med (Hagerstown) 2006;7:464-9
44. Chan KL, Teo K, Tam J, Dumesnil JG; Astronomer Investigators. Rationale, design and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Am Heart J 2007;153:925-31
45. Rossebo AB, Pedersen TR, Allen C, et al. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am J Cardiol 2007;99:970-3
46. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DE Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention? Expert Opin Ther Targets 2008;12:809-20